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Since 2015 in the United States (US), the US Neisseria 
meningitidis  urethritis clade (US_NmUC) has caused 
a large multistate outbreak of urethritis among het-
erosexual males. Its ‘parent’ strain caused numerous 
outbreaks of invasive meningococcal disease among 
men who have sex with men in Europe and North 
America. We highlight the arrival and dissemination 
of US_NmUC in the United Kingdom and the emer-
gence of multiple antibiotic resistance. Surveillance 
systems should be developed that include anogenital 
meningococci.
From 2015, the United States (US) has experienced a 
large multistate outbreak of meningococcal urethri-
tis among predominantly heterosexual males due to 
a novel non-serogroupable strain - the US  Neisseria 
meningitidis  urethritis clade (US_NmUC) [1]. As a pre-
caution, in November 2018, Public Health England 
extended meningococcal surveillance to include ano-
genital meningococci retrieved from adults attend-
ing four sexual health clinics in London and four in 
Manchester. Among 72 isolates collected from sympto-
matic or NAAT-positive sexual health clinic attendees 
during 2019, two were found to belong to the US_
NmUC strain. Here we describe the United Kingdom 
(UK) cases and corresponding isolates in the context of 
the US experience and consider the implications going 
forward.
 
Isolation and phylogenetic analysis
The UK US_NmUC isolates were collected in Manchester 
(August 2019) and London (December 2019), respec-
tively. They were both non-serogroupable with geno-
type P1.5–1,10–8:F3–6:ST-11 (cc11). Draft genomes 
were submitted to the PubMLST  Neisseria  database 
(IDs 72327 and 72325, respectively). Both were from 
rectal swabs from HIV-negative white British men who 
have sex with men (MSM) in their thirties/forties who 
reported unprotected oral and anal sex with three to six 
partners in the 3 months before being diagnosed. Both 
were users of pre-exposure prophylaxis (PrEP). There 
were no co-infections with gonorrhoea, chlamydia, HIV 
or syphilis. In addition, hepatitis B and C were ruled 
out in Manchester and  Mycoplasma genitalium  was 
ruled out in London. The London case had no history 
of travel in the previous 3 months. No recent travel was 
documented for the Manchester case, however, this 
did not form part of the sexual history. The case from 
Manchester was asymptomatic and had been success-
fully treated for gonococcal infection of the rectum 3 
months prior (ceftriaxone 1 g, as per national guide-
lines [2]). The case from London had a 5-day history 
of rectal discharge and pain. On examination, proctos-
copy was normal and microscopy showed mucus only. 
Neither patient had symptoms of urethritis. There were 
no known links between the patients.
On a phylogenetic analysis including 209 US US_NmUC 
isolates, obtained between 2013 and 2016 [1], the UK 
isolates formed a monophyletic clade suggesting a 
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single introduction into the UK and subsequent dissem-
ination (Figure). Both isolates were sensitive to cefotax-
ime and resistant to penicillin (MIC 0.38 mg/L) with the 
same  penA  allele (allele 316; reduced susceptibility-
associated mutations F504L, A510V, I515V, H541N, 
I566V) as the US isolates. The isolate from London 
was resistant to ciprofloxacin (MIC 0.38 mg/L) having 
acquired part of a gonococcal DNA gyrase (gyrA) gene. 
It had also acquired a frameshifted gonococcal malt-
ose phosphorylase gene making it unable to utilise 
maltose and giving it a carbohydrate utilisation profile 
more typically associated with gonococci (glucose pos-
itive (+), maltose negative (-), sucrose negative (-), 
lactose negative (-)). Both UK US_NmUC isolates pos-
sessed the same gonococcal  aniA  and  norB  alleles as 
the majority (196/209) of the US isolates [1]. Separate 
searches of the PubMLST Neisseria database (accessed 
30/03/20) for all non-serogroupable cc11 genomes > 1 
million base pairs (Mbp) (n = 247) and serogroup not 
stated cc11 genomes > 1 Mbp (n = 515) yielded 215 US_
NmUC genomes all of which were from the US (n = 213) 
or the UK (n = 2) (data not shown). 
Discussion and conclusions
Neisseria meningitidis  is principally a harmless 
commensal of the oropharynx and is carried by ca 10% 
of the population at any time. Very rarely, meningococci 
cause invasive disease including meningitis and/or 
sepsis. Diverse meningococci have also been reported 
to infect the anogenital tract, albeit rarely, with or 
without clinically indistinguishable gonorrhoea-like 
symptoms such as urethritis, cervicitis or proctitis [3]. 
The association of the US_NmUC strain with urethritis 
represents a marked shift from this general diversity. 
In the US, in one clinic, it accounted for ca 20% of all 
Gram-negative, oxidase-positive diplococci on urethral 
culture from men [4]. It has also caused recurrent epi-
sodes of urethritis [5], neonatal conjunctivitis [6] and, 
despite being acapsulate, at least five cases of inva-
sive disease, although the immune status of these 
patients was not reported [1]. The strain has been 
reported to be susceptible to ceftriaxone, azithromycin 
and ciprofloxacin and to have intermediate suscepti-
bility to penicillin [4,6]. The US_NmUC strain exhibits 
several gonococcus-like adaptations to the anogen-
tial niche, including the ability to grow anaerobically 
having acquired gonococcal  aniA  and  norB  genes 
concerned with nitrite metabolism. The permanent lack 
of a capsule is due to the deletion of several capsule 
synthesis genes, including part of the serogroup C 
determinant gene [7].
The US_NmUC strain emerged around the year 2011 
and forms part of a broader, predominantly serogroup 
C strain (PorA subtype P1.5–1,10–8: ST-11 complex) 
that, as well as causing invasive disease within the 
general community, has caused multiple outbreaks of 
serogroup C invasive disease among MSM in Europe 
and North America [8-10]. Phylogenetically, the isolates 
responsible for community cases and MSM outbreaks 
were broadly interspersed [11], however, discrete 
Figure 
Neighbor-Net phylogenetic network analysis of United 
States (US) (n = 209) and United Kingdom (n = 2) US 






UK: United Kingdom; US: United States; US_NmUC: US Neisseria 
meningitidis urethritis clade.
The US US_NmUC isolates [1] formed two sub-strains. The UK 
isolates (PubMLST IDs 72325 and 72327) formed a monophyletic 
clade close to the evolutionarily more recent sub-strain as 
indicated by the relative position of the non-US_NmUC reference 
genome (M21273; PubMLST ID 47235). The reference genome 
(P1.5–1,10–8:F3–6: ST-2724 (cc11) is the complete circular 
genome of a closely related non-US_NmUC invasive serogroup C 
isolate and provided a reference for several aspects of the study 
by Retchless and colleagues [1] including the estimation of an 
evolutionary timeline for the US_NmUC strain [1]. In the present 
study, genomes were compared gene-by-gene in terms of 1,605 
core genes using the PubMLST genome comparator tool [17]. The 
distance matrix generated was visualised using SplitsTree4 [18]. 
The scale bar represents the number of different loci among the 
1,605 loci compared.
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clustering of invasive MSM isolates and non-US_NmUC 
urethritis and proctitis isolates has been reported. 
Furthermore, all but one of the corresponding isolates 
had acquired an active  aniA  gene of meningococcal 
origin, in contrast to the gonococcal  aniA  of the US_
NmUC strain [12]. Interestingly, the non-US_NmUC 
urethritis/proctitis isolates, like gonococci, did not 
express factor H-binding protein (fHbp) due to disrup-
tion of the fhbp gene. All but one of the invasive MSM 
isolates, meanwhile, retained their ability to express 
fHbp which is important for survival within the blood 
stream and, therefore, their ability to cause invasive 
disease [12]. Concerningly, the broader strain has a 
demonstrated propensity to escape both capsular and 
subcapsular meningococcal vaccines [13].
Implications of the emergence of meningococci 
adapted to the anogenital niche
Aside from re-occurring invasive disease outbreaks 
among MSM, the association of this broad strain with 
sexual transmission, and its adaptation to the anogeni-
tal niche, pose several threats. Widespread acquisition 
of gonococcal DNA by US_NmUC strain isolates has 
already been demonstrated [1], raising the prospect of 
further acquisition of gonococcal antibiotic resistance 
determinants, as has now been observed with one of 
the UK isolates. Such genes may be passed onto more-
typical meningococci, including hypervirulent lineages 
that typically reside within the oropharynx. Congenital 
complement deficiencies, excluding mannose-binding 
lectin deficiency, are estimated to affect approximately 
0.03% of the general population [14] and increase 
the risk of invasive meningococcal disease by up 
to 10,000-fold. Similarly, the terminal complement 
pathway inhibitor, eculizumab, which is used to treat 
paroxysmal nocturnal haemoglobinuria and atypical 
haemolytic uraemic syndrome, is associated with up 
to 2,000-fold increased incidence of invasive menin-
gococcal disease. This includes disease caused by 
unencapsulated strains, such as the US_NmUC strain, 
that would not normally cause disease in healthy indi-
viduals [15]. These individuals are recommended to 
receive meningococcal vaccination and long-term peni-
cillin prophylaxis [16]. To account for the existence of 
relatively rare penicillin-resistant strains, ciprofloxa-
cin may also be prescribed as a back-up should the 
patient experience symptoms of invasive meningo-
coccal disease. The emergence of resistance to both 
penicillin and ciprofloxacin in one of the UK US_NmUC 
isolates, coupled with a propensity to escape licenced 
meningococcal vaccines is, therefore, very concerning. 
More generally, penicillin is prescribed in emergency 
situations when invasive meningococcal disease is 
suspected and ciprofloxacin is used as post-exposure 
prophylaxis to clear nasopharyngeal carriage.
A call for vigilance
This is the first report of the US_NmUC strain outside 
of the US. Although the numbers are low, it is notewor-
thy that the strain has, thus far, only been observed 
in MSM in the UK rather than in heterosexual males, 
as was predominantly the case in the US. The increas-
ing burden of gonorrhoea and emerging resistance to 
last-line antibiotics is already a major global threat 
and meningococci could follow the same trajectory. In 
the UK, presumptive gonorrhoea, as indicated by clini-
cal features and Gram stain, is prescribed on-the-day 
anti-gonococcal treatment and partner notification is 
initiated [2]. Immediately-indistinguishable meningo-
coccal infections presenting as such will also be cov-
ered by anti-gonococcal treatment, however, patients 
subsequently found to culture only meningococci (at 
least 24 hours later) would not usually be recalled, 
partner notification would not be done post-hoc, and 
a test of cure would not be done. Thus, if the UK and 
countries further afield are to avoid an outbreak simi-
lar to that seen in the US, more intensive management 
and follow up as per gonococcal disease may be indi-
cated. Clinicians, microbiologists and public health 
teams, therefore need to remain vigilant and consider 
developing surveillance systems to include anogenital 
meningococci.
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